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The three peroxisome proliferator-activated receptors (PPARa, PPARb, and PPARg) are ligand-activated
transcription factors belonging to the nuclear hormone receptor superfamily. They are regarded as being
sensors of physiological levels of fatty acids and fatty acid derivatives. In the adult mouse skin, they are found in
hair follicle keratinocytes but not in interfollicular epidermis keratinocytes. Skin injury stimulates the
expression of PPARa and PPARb at the site of the wound. Here, we review the spatiotemporal program that
triggers PPARb expression immediately after an injury, and then gradually represses it during epithelial repair.
The opposing effects of the tumor necrosis factor-a and transforming growth factor-b-1 signalling pathways on
the activity of the PPARb promoter are the key elements of this regulation. We then compare the involvement of
PPARb in the skin in response to an injury and during hair morphogenesis, and underscore the similarity of its
action on cell survival in both situations.
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INTRODUCTION
The peroxisome proliferator-activated receptor a (PPARa) was
identified in the early 1990s as the target of compounds that
cause proliferation of peroxisomes in rodent liver (Issemann
and Green, 1990). Three PPAR isotypes were then identified
in rodents, frogs, fishes, and humans, named PPARa
(NR1C1), PPARb/d (NR1C2, called PPARb herein) and PPARg
(NR1C3) (Desvergne and Wahli, 1999). They are ligand-
induced transcription factors belonging to the nuclear
hormone receptor superfamily that also includes, amongst
others, retinoid X receptors, the vitamin D receptor, thyroid
hormone receptors, and estrogen receptors.
PPARs are considered to be sensors, especially
for polyunsaturated fatty acids and diverse fatty acid
derivatives (Forman et al., 1997; Kliewer et al., 1997;
Krey et al., 1997). Polyunsaturated fatty acids like
arachidonic acid or linoleic acid are potent activators of
the three PPARs. Arachidonic acid derivatives such as
leukotrienes and prostaglandins are PPAR agonists that
show higher selectivity towards PPARa, PPARb, and
PPARg, respectively (Kersten and Wahli, 2000). In addition,
several synthetic marketed drugs are PPAR ligands, such as
the fibrates used to treat dyslipidemia through PPARa
activation, and the antidiabetic thiazolidinediones that
activate PPARg.
From a structural point of view, PPARs display the
characteristic organization of nuclear receptors. The N-termi-
nal A/B domain containing a putative ligand independent
transactivation function (AF-1) is flanked by the C-domain
which binds DNA via a two zinc finger motif. The C-domain
is linked by a short hinge domain (D) to the C-terminal
ligand-binding domain, also called the E/F domain, which
contains the ligand-dependent transactivation function
AF-2. In the PPARa and g isotypes, the ligand-independent
transactivation function can be regulated by phosphorylation
via activation of the mitogen-activated protein kinase path-
way (Diradourian et al., 2005; Gelman et al., 2005). Upon
fixation of an agonist, a conformational change in the
structure of the ligand-binding domain creates the interface
required for interactions with coactivators, such as SRC-1 or
CBP/p300, which results in the transactivation of target
genes. Alternatively, PPARs can exert transrepression of gene
activity via mechanisms that were reviewed recently (Feige
et al., 2006).
Mainly expressed in the liver and brown adipose tissue,
but also found at lower levels in the gut, muscle, and kidney,
PPARa is involved in lipid catabolism (Kersten et al., 2000)
and exerts anti-inflammatory effects (Delerive et al., 2001;
Genolet et al., 2004; Kostadinova et al., 2005). Interestingly,
PPARa is also expressed in the epidermis following a skin
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injury, as will be discussed below (Michalik et al., 2001).
PPARg is involved in adipocyte differentiation and lipid
storage, as well as in the control of inflammatory reactions. It
is mostly expressed in adipose tissue, gut, and the immune
system and is induced in the liver by a high-fat diet (Kersten
et al., 2000). PPARb, which has remained the less understood
isotype, displays an ubiquitous expression often at levels that
are higher than those of the two other isotypes (Escher et al.,
2001). Its upregulation in the murine interfollicular epidermis
is of particular importance during skin wound healing
(Michalik et al., 2001; Tan et al., 2001).
PPAR EXPRESSION IN HEALTHY AND INJURED SKIN
Single cell metabolism as well as intercellular interactions
depend on complex mechanisms that ensure cell and tissue
maintenance and renewal in a highly coordinated manner.
The skin is a barrier against various environmental aggres-
sions and dehydration, and is prone to be wounded.
Following an injury and the inflammatory response it
induces, repair is a survival process that involves activation
of cells and their interactions with the extracellular matrix
(ECM) to restore the integrity of the wounded area (Midwood
et al., 2004). This repair is a life-saving priority process
initiated by the disruption of the blood vessels that in turn
triggers platelet activation and release of cytokines and
growth factors. Immune cells invade the newly formed blood
clot, and become involved in cell debris phagocytosis and
the secretion of many inflammatory cytokines (Werner and
Grose, 2003). This initial inflammatory stage is followed by
the proliferative and migratory phases of the repair process.
The proliferation of activated keratinocytes and their migra-
tion following directional sensing contribute to the re-
epithelialization of the wound. In parallel, dermal repair
involves recruitment and proliferation of fibroblasts – which
produce extracellular matrix—and angiogenesis—which
provides blood supply to the newly regenerated tissue.
Fibroblasts also secrete growth factors stimulating re-epithe-
lialization (Birch et al., 2005). Their differentiation into myo-
fibroblasts allows wound contraction and tissue remodelling,
the last steps in the wound-repair process (Desmouliere et al.,
2005).
PPARa and PPARb expression is upregulated during the
repair process, whereas PPARg remains undetectable in the
wounded murine interfollicular epidermis. The upregulation
of PPARa is transient and correlates with the inflammatory
phase, while that of PPARb lasts over the entire healing
process. The absence of PPARa in PPARa-null mice results in
only a transient delay in wound repair, whereas completion
of wound closure in animals lacking PPARb is retarded for
2–3 days (Michalik et al., 2001).
PPARa AND PPARb ARE IMPORTANT PLAYERS IN THE
KERATINOCYTE RESPONSE TO SKIN INJURY
As mentioned above, the kinetics of wound closure in PPARa
null mice reveal no overall delay in healing. However, during
the first 4 days following an injury a transient delay
coinciding with the inflammatory phase is observed, but
later on normal wound-healing efficiency is restored.
Monitoring inflammatory cell infiltration revealed an im-
paired recruitment of neutrophils and monocytes/macro-
phages to the wound bed in PPARa/ animals (Michalik
et al., 2001). Transgenic mice expressing a dominant-
negative form of PPARa in the epidermis (PPARaD13) were
used to determine whether this observation is the conse-
quence of the genetic ablation of PPARa in immune cells and
fibroblasts, or arises from a defect in keratinocytes. Interest-
ingly, the PPARaD13 mice displayed the same pattern in
wound closure as the PPARa/ mice, with a transient delay
in repair overlapping with the inflammatory phase (Michalik
et al., 2005). No defect in immune cell recruitment was
observed in these mice. However, an increase in the
expression of tumor necrosis factor (TNF)-a indicated that
the inflammatory reaction is exacerbated in PPARaD13-
wounded skin. This revealed a loss of control of the
inflammatory process in the transgenic animals.
The upregulation of PPARb expression in wound healing is
correlated to keratinocyte proliferation, adhesion, and
migration upon the extracellular matrix in order to re-
epithelialize the wounded region. Consistent with this, the
delay observed in wound repair of PPARbþ / mice overlaps
with these healing phases. The key molecular processes
responsible for PPARb upregulation in keratinocytes were
elucidated using primary keratinocyte cultures and a condi-
tioned medium to mimic the inflammatory phase of wound
repair (Tan et al., 2001). Following the release of pro-
inflammatory cytokines such as TNF-a, the stress-associated
protein kinase pathway is activated, leading to the stimula-
tion of PPARb expression through AP-1 binding to its
promoter. In parallel, activation of the primary keratinocytes
by pro-inflammatory cytokines triggers the production of an
endogenous ligand for PPARb (Tan et al., 2001). PPARb then
plays the role of a key transcription factor relaying
inflammatory signals into cellular responses such as inflam-
mation-induced differentiation, control of proliferation and
resistance to apoptosis in keratinocytes. In the wound-healing
process, PPARb promotes cell survival through a direct
activation of the genes coding for integrin-linked kinase and
3-phosphoinositide-dependent kinase-1, and consequent
activation of the PKBa/Akt1 kinase (Di-Poi et al., 2002). In
addition, PPARb is implicated in cell adhesion and migration
as reflected by defects seen in the primary keratinocyte
cultures (Tan et al., 2001).
Using an apoptotic-derived conditioned medium that
mimics the late re-epithelialization or remodelling stages of
wound healing, we have identified transforming growth
factor (TGF)-b1 as the cytokine that antagonizes TNF-a-
induced PPARb expression in keratinocytes (Tan et al., 2004).
This inhibitory effect occurs through the interaction of c-JUN
with Smad3 (a downstream effector of TGF-b1 signalling),
preventing the binding of c-JUN-p300 to the AP-1 site in the
PPARb promoter. Interestingly, both TNF-a induction of
PPARb expression, and its downregulation by TGF-b1
converge on the same AP-1 response element, either bound
by or depleted of c-jun. A prolonged expression of PPARb
obtained through genetic ablation of Smad3 (Smad3/)
(Ashcroft et al., 1999), or through early treatment with
www.jidonline.org 31
G Icre et al.
Functions of the Peroxisome Proliferator-Activated Receptor
TGF-b1 (day 0) accelerates skin wound closure (Tan et al.,
2005) (Figure 1). In agreement with the sustained expression
of PPARb during wound closure, a prolonged increase of
PKBa/Akt1 activity was also observed in these conditions.
According to the role of TGF-b1 as a chemo-attractant for
macrophages and neutrophils (Wahl et al., 1987), an increase
in the number of recruited macrophages into the wound bed
was observed in the animals treated with TGF-b1 on the day
of injury, compared to vehicle-treated animals (Tan et al.,
2005). Therefore, we propose that early recruited macro-
phages produce a sufficient amount of inflammatory cyto-
kines to overcome the inhibitory effect of TGF-b1 on PPARb
expression, and upregulate its expression as previously
described (Tan et al., 2001). Conversely, exogenous appli-
cation of TGF-b1 on a skin wound at day 2 following the
injury had opposite effects, with PPARb expression prema-
turely downregulated (Figure 1). As a consequence there was
a decrease in PKBa/Akt1 activity and a transient but
significant delay in wound closure (Tan et al., 2005).
In summary, spatial and temporal effects mediated by
cytokines modulate the response of keratinocytes during a
stress situation such as skin injury. Cytokines, such as TNF-a
and TGF-b1, are mainly produced by the cells populating the
wound bed. They attract and activate surrounding keratino-
cytes that proliferate and migrate through the provisional
matrix temporarily deposited in the clot. Activated keratino-
cytes produce TNF-a that stimulates the expression of PPARb
via the SAP-kinase pathway, until TGF-b1 antagonizes this
effect and suppresses PPARb expression. This temporal
regulation is a key process in regenerating epithelium.
INVOLVEMENT OF PPARb IN HAIR FOLLICLE
MORPHOGENESIS
When reactivated in interfollicular epithelium following
injury, PPARb plays important roles in the response of
keratinocytes to stress. In the hair follicle, PPARb is
constitutively expressed, and, like many other nuclear
hormone receptors, has a role in normal hair follicle
development (Michalik et al., 2001; Alonso and Rosenfield,
2003; Di-Poi et al., 2005). Hair follicle morphogenesis
depends on epithelium–mesenchyme interactions (Alonso
and Rosenfield, 2003) and on hormonal signalling, which is
important in modulating hair cycling from anagen to telogen.
PPARb regulates postnatal hair growth, but not the initiation
of hair morphogenesis, as the total number of hair follicles is
similar in PPARbþ /þ and PPARb/ mice (Di-Poi et al.,
2005). However, a lower hair score for hair follicle
morphogenesis in PPARb/ compared to PPARbþ /þ mice
showed that PPARb is required for hair follicle growth. In
agreement with this observation, treatment of skin organ
cultures with a PPARb agonist increases the hair score in
PPARbþ /þ but not in the PPARb/ explants. Developing
hair follicles of PPARb-deficient mice at postnatal day 4 (P4)
display an increased amount of apoptotic keratinocytes
compared to their wild-type counterparts, in which apoptotic
keratinocytes are restricted to the suprabasal layers of the
interfollicular epidermis (Figure 2b). Consistent with the
known function of PPARb in regulating the activity of PKBa/
0 2 4 6 8 10 12 14 16 18
0 2 4 6 8 10 12 14 16 18
0 2 4 6 8 10 12 14 16 18
0 2 4 6 8 10 12 14 16 18
Ex
pr
es
sio
n 
pa
tte
rn
 o
f P
PA
R
a
n
d 
ta
rg
et
 g
en
e 
ac
tiv
at
io
n
Ex
pr
es
sio
n 
pa
tte
rn
 o
f P
PA
R
a
n
d 
ta
rg
et
 g
en
e 
ac
tiv
at
io
n
Ex
pr
es
sio
n 
pa
tte
rn
 o
f P
PA
R
a
n
d 
ta
rg
et
 g
en
e 
ac
tiv
at
io
n
Ex
pr
es
sio
n 
pa
tte
rn
 o
f P
PA
R
a
n
d 
ta
rg
et
 g
en
e 
ac
tiv
at
io
n
Ki
ne
tic
 o
f w
ou
nd
 c
lo
su
re
Ki
ne
tic
 o
f w
ou
nd
 c
lo
su
re
Ki
ne
tic
 o
f w
ou
nd
 c
lo
su
re
Ki
ne
tic
 o
f w
ou
nd
 c
lo
su
re
PPAR ILK, PDK1 PKB/Akt1 Survival Growth arrest
RemodelingRe-epithelializationInflammation
PPAR+/+
PPAR+/+
Application of TGF-1
at day 0
PPAR+/+
Application of TGF-1
at day 2
Smad3−/−
Figure 1. Overview of the consequences of the crosstalk between PPARb
and the TGF-b1 pathway in skin repair. Upon injury pro-inflammatory
cytokines such as TNF-a are produced by the infiltrating immune cells
contributing to PPARb re-expression in the interfollicular epidermis through
an AP-1 response element in PPARb promoter (Tan et al., 2001). Activated
PPARb regulates the expression of integrin-linked kinase and 3-phosphoino-
sitide-dependent kinase-1, which contributes to PKBa/Akt1 activation by
phosphorylation to protect keratinocytes from apoptosis (Di-Poi et al., 2002).
Along with the wound-repair progression into the re-epithelialization and
remodelling phase, both wound fibroblasts and immune cells produce
TGF-b1. Through the activation of the TGF-b1/Smad3 pathway, TGF-b1
antagonizes the TNF-a effect by preventing the binding of cJUNp300 on the
AP-1 site in the PPARb promoter (Tan et al., 2004). As illustrated in the
graphic representation of wound closure, delayed repression of PPARb
expression obtained through genetic ablation of Smad3 accelerates wound
healing, whereas its inhibition following topical application of TGF-b1 at day
2 after injury leads to a transient delay in wound closure. Alternatively, early
exposure to TGF-b1 at day 0 following injury leads to a prolonged expression
of PPARb and accelerated wound repair probably due to increased
recruitment of inflammatory cells by TGF-b1. Blue lines represent the kinetics
of wound closure, red lines represent PPARb expression. Gray lines on each
graph are a reminder of the wild-type pattern of both PPARb expression and
kinetics of wound closure.
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Akt1 (Di-Poi et al., 2002), and with the role of PKBa/Akt1 in
hair follicle morphogenesis (Rosenfield et al., 2000), the
spatio-temporal activation of PPARb in the developing hair
follicles protects keratinocytes from apoptosis via the PKBa/
Akt1 pathway. PKBa/Akt1 activity in PPARbþ /þ skin is
reflected in the increase of the phosphorylation of antiapop-
totic factors, such as FKHR and Bad. In PPARb/ skin, this
activation is postponed until P7. These data show that the
delay in hair follicle morphogenesis seen in the skin of
PPARb/ mice is the consequence of a reduced antiapopto-
tic activity of PKBa/Akt1. In addition, a slight decrease in the
number of proliferative cells was also observed in the
PPARb/ mice compared to the wild-type skin.
Although PPARb is expressed constitutively in hair follicles
at all stages of their morphogenesis, it seems to be important
only for hair follicle elongation (P4), which suggests that a
PPARb ligand is produced at that time. Cyclooxygenase-2
(COX-2) is known to produce arachidonic acid derivatives
that are potent ligands of PPARb. Moreover, COX-2 was
shown to be active in the developing hair follicles (Muller-
Decker et al., 2003), where its stimulation parallels the action
of PPARb. In fact COX-2 expression is upregulated in hair
follicle keratinocytes from P1 to P4 by dermal signals
produced by the dermal papilla (Millar, 2002; Zeng et al.,
2002). In line with this expression pattern, the COX-2-
specific inhibitor (NS-398) delays hair follicle morphogenesis
in a dose-dependant manner when applied to PPARbþ /þ but
not to PPARb/ skin explants (Di-Poi et al., 2005). More-
over, hepatocyte growth factor treatment increases COX-2
expression in both PPARbþ /þ and PPARb/ keratinocytes
in a dose-dependent manner. Importantly, exposure of
PPARbþ /þ keratinocytes to hepatocyte growth factor leads
to an increase in the activity of PPARb, as reflected by
increased expression levels of 3-phosphoinositide-dependent
kinase-1 and integrin-linked kinase, and increased phosphor-
ylation of PKBa/Akt1 (Di-Poi et al., 2005).
In summary, hepatocyte growth factor produced by the
dermal papilla fibroblasts triggers a temporal induction of
COX-2 activity in hair follicle keratinocytes. COX-2 in turn
activates PPARb via ligand production. The subsequent
activation of the PKBa/Akt1 pathway protects hair follicle
keratinocytes from premature apoptosis, thus enabling them
to participate in normal hair follicle morphogenesis (Di-Poi
et al., 2005) (Figure 2).
CONCLUSION
The expression pattern of PPARa and PPARb in mouse
epidermis suggests a dual role for these nuclear hormone
receptors involved both in skin development and in repair
after an injury. While both receptors are constitutively
expressed in the hair follicles, they remain undetectable in
the normal adult mouse interfollicular epidermis, in contrast
to their expression in the embryonic epidermis. A full
thickness injury of the adult skin induces a strong re-
activation of PPARa and PPARb expression in these cells.
Genetically engineered PPARa/, PPARaD13, PPARbþ /,
and PPARb/ mice were valuable tools in deciphering the
roles of PPARa and PPARb in the mechanisms of skin wound
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Figure 2. PPARb in hair follicle morphogenesis. (a) PPARb is constitutively expressed in hair follicles. It is transiently activated by ligands produced during
hair follicle morphogenesis via COX-2 activation. COX-2 is activated in hair follicle keratinocytes via the paracrine effect of hepatocyte growth factor
(HGF) through its receptor Met. (b) As described for wound repair, PPARb expression and activation during morphogenesis protects hair follicle keratinocytes
from apoptosis. The TUNEL assay revealed an increased number of apoptotic cells in developing hair follicles from PPARb/ mice (day 4 postnatal P4,
hair follicles at stage 1–4 according to the classification by Paus et al., 1999). (c) Quantification of proliferative and apoptotic cells in developing hair follicles at
day P4: PPARb/ hair follicle keratinocytes, compared to their wild-type counterparts display less proliferation and increased apoptosis as revealed by
proliferating cell nuclear antigen (PCNA)/5-bromodeoxyuridine staining (BrdU) and TUNEL assay, respectively.
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repair. PPARa/ and PPARaD13 mice display a transient
delay in wound closure that overlaps with the inflammatory
phase of healing. This delay correlates with the impaired
recruitment of inflammatory cells to the wound bed of injured
PPARa/ mice. It is most probably due to a keratinocyte-
dependent defect since it was also observed in PPARaD13
mice that present an exacerbated production of TNF-a after
an injury. These two observations converge in suggesting an
impaired inflammatory response in both types of mutant
animals. They lend support to the notion that PPARa controls
the inflammatory phase of skin repair. TNF-a was found to be
the trigger of inflammation-induced expression and activation
of PPARb in the wounded epithelium via both the activation
of the AP-1 transcription factor complex that binds to a
response element in a PPARb promoter, and the production
of an endogenous PPARb ligand. An opposing signal from the
TGF-b1 pathway converges at the same AP-1 response
element leading to a decrease in PPARb expression at the
later stages of repair. During the window of PPARb
expression and activation controlled by the timely secretion
of TNF-a and TGF-b1 by immune cells and myofibroblasts,
respectively, keratinocytes are protected from cell death via
the activation of the PKBa/Akt1 pathway.
In addition to this stress response, epithelial–mesenchymal
interactions are also involved in the mechanisms of hair
follicle development. During hair follicle morphogenesis,
fibroblasts from the dermal papilla produce the paracrine
growth factor hepatocyte growth factor to which hair follicle
keratinocytes respond by stimulation of the COX-2 gene.
Enhanced COX-2 levels lead to increased PPARb ligand
production. In this case, timely activation of the constitutively
expressed PPARb induces the PKBa/Akt1 pathway that
protects follicular keratinocytes from premature apoptosis.
In conclusion, PPARa and PPARb are key regulators of skin
homeostasis. They control repair after an injury, and
participate in normal hair follicle morphogenesis.
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